Clinical Trial

Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.

Study acronym: SPIDER-MEN
Recruiting
View on ClinicalTrials.gov →
Summary
High-risk meningiomas always require postsurgical radiation treatment. Recent evidence has shown that increased radiation therapy dose may be associated with increased intracranial control of disease. In order to better define the volume of radiation treatment, the addition of PET imaging with somatostatin receptor tracers adds additional information compared to encephalon MRI with MoC alone.The present study aims to investigate whether radiation treatment with higher doses than the standard and defined using PET imaging can be safe and at the same time effective in order to increase progression-free survival in high-risk meningiomas.
Trial Details
NCT Number NCT06830356
Lead Sponsor Centro di Riferimento Oncologico - Aviano
Conditions Meningioma
Enrollment 53 participants
Start Date 2024-12-23
Primary Completion 2037-12-23 (estimated)
Study Completion 2037-12-23 (estimated)
Updated on ClinicalTrials.gov 2025-02-17